Citadel Advisors’s GenMark Diagnostics, Inc GNMK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-443,189
| Closed | -$10.6M | – | 14975 |
|
|
2021
Q1 | $10.6M | Buy |
443,189
+332,232
| +299% | +$6.17M | ﹤0.01% | 2882 |
|
|
2020
Q4 | $1.62M | Sell |
110,957
-293,343
| -73% | -$3.89M | ﹤0.01% | 5826 |
|
|
2020
Q3 | $5.74M | Sell |
404,300
-96,441
| -19% | -$1.47M | ﹤0.01% | 2958 |
|
|
2020
Q2 | $7.37M | Buy |
500,741
+474,989
| +1,844% | +$4.83M | ﹤0.01% | 2572 |
|
|
2020
Q1 | $106K | Sell |
25,752
-138,459
| -84% | -$649K | ﹤0.01% | 8601 |
|
|
2019
Q4 | $790K | Sell |
164,211
-205,304
| -56% | -$1.13M | ﹤0.01% | 6020 |
|
|
2019
Q3 | $2.24M | Buy |
369,515
+85,450
| +30% | +$533K | ﹤0.01% | 4303 |
|
|
2019
Q2 | $1.84M | Sell |
284,065
-12,320
| -4% | -$86.8K | ﹤0.01% | 4648 |
|
|
2019
Q1 | $2.1M | Buy |
296,385
+171,386
| +137% | +$1.13M | ﹤0.01% | 4389 |
|
|
2018
Q4 | $607K | Buy |
124,999
+105,198
| +531% | +$548K | ﹤0.01% | 6107 |
|
|
2018
Q3 | $145K | Sell |
19,801
-106,983
| -84% | -$785K | ﹤0.01% | 8421 |
|
|
2018
Q2 | $808K | Buy |
126,784
+60,991
| +93% | +$403K | ﹤0.01% | 5569 |
|
|
2018
Q1 | $358K | Sell |
65,793
-14,816
| -18% | -$73.6K | ﹤0.01% | 6460 |
|
|
2017
Q4 | $336K | Sell |
80,609
-7,534
| -9% | -$45.3K | ﹤0.01% | 6273 |
|
|
2017
Q3 | $848K | Sell |
88,143
-849,194
| -91% | -$8.82M | ﹤0.01% | 4546 |
|
|
2017
Q2 | $11.1M | Buy |
937,337
+153,572
| +20% | +$1.96M | 0.01% | 1379 |
|
|
2017
Q1 | $10M | Buy |
783,765
+402,832
| +106% | +$4.85M | 0.01% | 1435 |
|
|
2016
Q4 | $4.66M | Buy |
380,933
+285,106
| +298% | +$3.39M | ﹤0.01% | 2081 |
|
|
2016
Q3 | $1.13M | Buy |
+95,827
| New | +$925K | ﹤0.01% | 3681 |
|
|
2013
Q4 | – | Sell |
-420,401
| Closed | -$5.11M | – | 7240 |
|
|
2013
Q3 | $5.11M | Buy |
+420,401
| New | +$4.51M | 0.01% | 1578 |
|
Citadel Advisors's GNMK Position: Q2 2021 in Review
Citadel Advisors sold out of GenMark Diagnostics, Inc (GNMK) in Q2 2021, closing a stake of 443,189 shares — an estimated $10.6M sold.
Citadel Advisors first reported a position in GNMK in Q3 2013 and held it in 20 quarters. The position peaked at $11.1M in Q2 2017. 0 funds tracked by Wall St. Rank hold GNMK as of Q2 2021.
- Citadel Advisors reported no remaining GenMark Diagnostics, Inc position as of Q2 2021 after selling out during the quarter.
- Citadel Advisors sold 443,189 GenMark Diagnostics, Inc shares in Q2 2021, an estimated $10.6M.
- Citadel Advisors first reported a position in GenMark Diagnostics, Inc in Q3 2013 and held it in 20 quarters.
- Citadel Advisors's GenMark Diagnostics, Inc position peaked at $11.1M in Q2 2017.
- 0 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q2 2021.
Based on Citadel Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.